American Type Culture Collection

BIOMATERIAL MANUFACTURING SUITE IN SUPPORT OF NIH/NIAID AND THE GLOBAL INFECTIOUS DISEASE RESEARCH COMMUNITY - BIOMATERIAL MANUFACTURING SUITE IN SUPPORT OF NIH/NIAID AND THE GLOBAL INFECTIOUS DISEASE RESEARCH COMMUNITY PROJECT DIRECTOR: REBECCA BRADFORD, MBA, MS, PMP® PROJECT SUMMARY THE PROJECT IS TO CONSTRUCT AND COMMISSION A BIOMATERIAL MANUFACTURING SUITE (BMS) AS AN EXPANSION WITHIN THE HIGH CONTAINMENT FACILITY (HCF) CURRENTLY UNDER DESIGN AT THE AMERICAN TYPE CULTURE COLLECTION (ATCC). ATCC IS A NON-PROFIT ENTITY IN MANASSAS, VIRGINIA, SERVING THE FEDERAL GOVERNMENT FOR OVER 50 YEARS THROUGH OUR FEDERAL SOLUTIONS (AFS) DIVISION. THE PROPOSED AIM OF THE BMS IS TO PROVIDE MODERN AND REPRODUCIBLE LARGE-SCALE BIOMATERIAL MANUFACTURING CAPABILITIES FOR PRIORITY PATHOGENS. RESIDING WITHIN THE SOON-TO-BE-BUILT HCF, THE BMS WILL OFFER THE NATIONAL INSTITUTE OF HEALTH AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIH/NIAID) HIGH-THROUGHPUT AND RAPID DEVELOPMENT PIPELINES FOR BIOMATERIALS OF PUBLIC HEALTH CONCERN, INCLUDING THOSE OF EPIDEMIC OR PANDEMIC POTENTIAL. THE BMS WILL DIRECTLY SUPPORT FEDERAL AGENCIES AND THE INFECTIOUS DISEASE RESEARCH COMMUNITIES BY OPTIMIZING PATHOGENIC ORGANISMS’ GROWTH, PRODUCTION, AND CHARACTERIZATION FOR DOWNSTREAM USE. BY FUNDING THE BMS WITHIN THE PLANNED FACILITY, AFS CAN ENHANCE OUR SUPPORT TO NIH/NIAID THROUGH OUR ABILITY TO OFFER LARGE-SCALE STOCKS OF WELL-CHARACTERIZED CHALLENGE MATERIALS AT NO COST TO THE RESEARCH COMMUNITY THROUGH AFS MANAGED PROGRAMS, INCLUDING BEI RESOURCES. IN TURN, THIS WILL ACCELERATE INFECTIOUS DISEASE RESEARCH FOR VACCINE AND THERAPEUTIC DEVELOPMENT IN OUTBREAK SITUATIONS AND SERVE AS BIOLOGICAL STANDARDS FOR DEVELOPING DETECTION ASSAYS. AFS’ CURRENT MODULAR 7,500 FT2 HCF WAS BUILT IN 2007 AS A TEMPORARY SOLUTION TO FACILITATE THE EXPANDING NEEDS OF AFS’ HEALTH AND HUMAN SERVICES (HHS) PROGRAMS. THE FACILITY IS NOW OVER- EXTENDED WITH RESPECT TO LIFESPAN, CAPACITY, AND CAPABILITIES. AFS DUTIFULLY MAINTAINS THE UPKEEP OF THE CURRENT HCF TO SUPPORT THE EXTENSIVE NIH/NIAID REQUESTS FOR BIOLOGICAL PRODUCTS TO ADVANCE OUR MEDICAL COUNTERMEASURES AND ARSENAL AGAINST VARIANTS FOR THE RECENT ONSLAUGHT OF THE COVID- 19 PANDEMIC. AS A NON-PROFIT ORGANIZATION, ATCC HAS COMMITTED SEVERAL MILLION DOLLARS TO DESIGN AND CONSTRUCT A NEW HCF TO ENHANCE AND MODERNIZE OUR SUPPORT TO NIH. THE EXPLICIT GOAL OF THIS FUNDING IS TO INCLUDE THE DESIGN, CONSTRUCTION, AND COMMISSIONING OF THE BMS WITHIN THE FACILITY FOOTPRINT TO PROVIDE CRITICAL BIOLOGICAL MANUFACTURING CAPABILITIES IN THE BIOMEDICAL SPACE TO ACCELERATE TRANSLATIONAL RESEARCH FOR VACCINE AND THERAPEUTIC DEVELOPMENT.

ATCC'S HIGH CONTAINMENT FACILITY RENOVATIONS IN SUPPORT OF NIAID AND PANDEMIC PREPAREDNESS - PROJECT SUMMARY: THE PROPOSED PROJECT AIMS TO RENOVATE ATCC'S HIGH CONTAINMENT FACILITY (HCF) AT THE AMERICAN TYPE CULTURE COLLECTION (ATCC) IN MANASSAS, VIRGINIA. ATCC'S 7,500 FT2 BIOCONTAINMENT FACILITY WAS BUILT IN 2007 WITH FUNDING FROM NIAID AND HAS BEEN DEDICATED TO DEVELOPING INFECTIOUS DISEASE STRAINS AND REAGENTS NEEDED TO RAPIDLY ADVANCE DIAGNOSTICS, VACCINES, AND THERAPEUTICS AGAINST PRIORITY PATHOGENS. SINCE 2003, ATCC HAS PARTNERED WITH NIAID TO CENTRALIZE AND PROVIDE CRITICAL SCIENTIFIC RESOURCES THROUGH THE BIODEFENSE AND EMERGING INFECTIONS RESOURCES (BEI RESOURCES) PROGRAM. THE NIAID ESTABLISHED BEI RESOURCES TO PROVIDE THE GLOBAL RESEARCH COMMUNITY WITH REAGENTS, TOOLS, AND INFORMATION FOR STUDYING CATEGORY A, B, AND C PRIORITY PATHOGENS, EMERGING INFECTIOUS DISEASE AGENTS, AND OTHER MICROBIOLOGICAL MATERIALS RELEVANT TO HUMAN HEALTH. OVER THE PAST 18 YEARS, ATCC HAS PROVIDED OVER 1,360,000 REAGENTS TO OVER 14,000 INVESTIGATORS AT 3,740 INSTITUTIONS IN 119 COUNTRIES SPANNING OVER 500 HUMAN PATHOGENS IN NIAID'S PRIORITY PORTFOLIO. DURING THIS PERIOD, BEI RESOURCES HAS PROVIDED CRITICAL MATERIALS FOR VITAL DISEASE OUTBREAKS, INCLUDING H1N1, MERS, EBOLA, AND ZIKA. OVER THE PAST TWO YEARS, ATCC HAS RAPIDLY CREATED MORE THAN 690 SARS-COV-2 PRODUCTS; ACQUIRED, PRODUCED, AND AUTHENTICATED MORE THAN 165 STOCKS OF SARS-COV-2 FOR BOTH GENERAL RESEARCH AND CHALLENGE STUDIES; AND SHIPPED MORE THAN 86,000 RESEARCH REAGENTS TO OVER 2,800 RESEARCHERS IN MORE THAN 70 COUNTRIES FOR THE DEVELOPMENT OF COUNTERMEASURES AND BASIC RESEARCH. THE MATERIAL PROVIDED BY BEI RESOURCES HAS BEEN CITED IN MORE THAN 1,800 SARS-COV-2 PUBLICATIONS SINCE FEBRUARY OF 2020. IN ADDITION, ATCC HAS FOSTERED COLLABORATION AND PARTNERSHIPS ACROSS NIAID PROGRAMS AND EXTERNAL WORKING GROUPS TO SHARE RESOURCES, INFORMATION, AND DATA TO ACCELERATE DISCOVERIES AND HARMONIZE SCIENTIFIC APPROACHES FOR PANDEMIC RESPONSE AND PREPAREDNESS. ATCC'S HIGH CONTAINMENT FACILITY HOUSES LABORATORIES ESSENTIAL FOR BSL-3 AND SELECT AGENT INFECTIOUS DISEASE RESEARCH, PRODUCT DEVELOPMENT, AND LARGE-SCALE REAGENT PRODUCTION FOR THE RESEARCH COMMUNITY. THIS PROPOSAL AIMS TO RENOVATE AND UPGRADE THE HVAC, DECONTAMINATION, AND SECURITY SYSTEMS. THE RENOVATIONS ALSO INCLUDE UPGRADES TO FIXED EQUIPMENT AND INTERIOR FINISHING IN THE FACILITY. THE RENOVATIONS WILL MODERNIZE THE FACILITY FOR USE BY 40 PH.D. ATCC SCIENTISTS, COLLABORATORS, AND LABORATORY SUPPORT STAFF. THE PRODUCTS AND SERVICES DEVELOPED IN THE FACILITY WILL SUPPORT THOUSANDS OF SCIENTISTS GLOBALLY EACH YEAR TO PREPARE AND RESPOND TO PANDEMICS. ATCC IS SEEKING THIS OPPORTUNITY FOR ENGAGEMENT WITH THE NIAID TO INVEST IN THIS FACILITY WHICH HAS BEEN FOUNDATIONAL FOR THE NATION'S PANDEMIC RESPONSE AND PREPAREDNESS.

AGRICULTURAL RESEARCH SERVICE - AMERICAN TYPE CULTURE COLLECTION BIOLOGICAL REPOSITORY PARTNERSHIP - THE NATIONAL BIO- AND AGRO-DEFENSE FACILITY (NBAF) WILL BE THE PREMIER CENTER OF SCIENTIFIC EXCELLENCE FOR THE STUDY OF TRANSBOUNDARY, EMERGING AND ZOONOTIC ANIMAL DISEASES IN THE UNITED STATES. RESEARCH CONDUCTED AT THE PLUM ISLAND DISEASE CENTER (PIADC) WILL TRANSITION TO NBAF ALONG WITH THE PIADC BIOLOGICAL COLLECTION. THIS COLLABORATIVE AGREEMENT BETWEEN ARS AND AMERICAN TYPE CULTURE COLLECTION (ATCC) WILL ESTABLISH A REMOTE REPOSITORY FOR BIOLOGICAL MATERIAL SUPPORTING THE ARS-NBAF IN PARTNERSHIP. THE MATERIAL WILL BE EXPANDED, PRESERVED AND WHEN APPROPRIATE, DISTRIBUTED BACK TO ARS OR OTHER ENTITIES.

GENOME-WIDE MAPPING (GWM) OF HOST PROTEOME: PAN ALPHAVIRUS PROTEOME INTERACTIONS FOR DISCOVERY OF BROAD-SPECTRUM COUNTERMEASURES

HOST-BASED ANTI-MICROBIAL PEPTIDES (AMP) AS THERAPEUTIC STRATEGIES FOR ALPHAVIRUS INFECTIONS

DEVELOPMENT OF A CONTINOUS INVITRO CULTURE SYSTEM FOR PLASMODIUM VIVAX